Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2020-11-13 Capital/Financing Update
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the pricing of a public marketed offering of units by Avicanna Inc. It details the terms of the offering, including the price per unit, the composition of the units, the agents involved, and the intended use of proceeds. It also discusses regulatory compliance and restrictions related to the offering. There is no financial statement, quarterly or annual report, or detailed financial analysis included. The document is clearly an announcement related to capital raising activities, specifically a public offering of securities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (9053 characters) and content confirm it is not a brief announcement or a report publication announcement but a full announcement of a financing event.
2020-11-13 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a term sheet describing a marketed public offering of units by Avicanna Inc. It details the securities offered, issue price, size, over-allotment option, warrants, use of proceeds, agents involved, agent fees, closing date, and listing information. The content focuses on capital raising and financing activities, specifically a public offering of securities. There is no indication that this is a full annual or interim report, audit report, earnings release, or any other type of report. The document is not a regulatory filing or announcement of a report but rather a detailed update on a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2020-11-13 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a marketed public offering of units by Avicanna Inc. It details the terms of the offering, regulatory filings related to the prospectus, the use of proceeds, and other offering-related information. There are no financial statements, earnings data, or detailed management analysis present. The document is not a full financial report but an announcement of a capital raising event. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (9370 characters) is sufficient to provide substantive details about the offering, not just a brief notice or report publication announcement.
2020-11-13 English
Decision Document (Preliminary).PDF
Regulatory Filings Classification · 95% confidence The document is a receipt from the Ontario Securities Commission for the filing of a Preliminary Short Form Prospectus dated November 12, 2020. It is a regulatory acknowledgment of a filing related to a prospectus, which is typically associated with capital raising activities. The document is short (914 characters) and serves as a receipt rather than the prospectus itself or a detailed financing update. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and acknowledgments that do not fit other specific categories.
2020-11-12 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'AVICANNA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE' and contains detailed financial data for the three months ended September 30, 2020, including revenues, expenses, net loss, balance sheet summaries, and operational highlights. It includes comprehensive financial statements and analysis for the quarter, which is a period shorter than a full fiscal year. The document also discusses business developments and corporate updates. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is IR with high confidence. Q3 2020
2020-11-12 English
Other.pdf
Regulatory Filings
2020-11-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.